{'fraction_non_alphanumeric': 0.025367156208277702, 'fraction_numerical': 0.0053404539385847796, 'mean_word_length': 6.211538461538462, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Combination of clofibrate and phenformin in the treatment of endogenous hypertriglyceridaemia (author's transl)].

Combined treatment with clofibrate and phenformin increased the lipid-lowering effect of clofibrate monotherapy in 15 patients with endogenous hypertriglyceridaemia significantly by ca. 10%. The therapeutic success was shown by a reduction in LDL-cholesterol and an additional reduction in VLDL-triglycerides. A clofibrate-induced rise in LDL-cholesterol could not be observed during the combined treatment. Thus combined treatment could be particularly advantageous in the prophylaxis of arteriosclerotic complications of endogenous hypertriglyceridaemia, provided that contra-indications of either of the preparations are excluded.